A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Dimerix Bioscience Pty Ltd
- Target Recruit Count
- 286
- Registration Number
- NCT05183646
- Locations
- π¦πΊ
Action3 Investigator Site 6, Melbourne, Australia
πΊπΈACTION3 Investigational Site 20, Coral Gables, Florida, United States
πΊπΈACTION3 Investigational Site 21, Springfield, Massachusetts, United States
Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Dimerix Bioscience Pty Ltd
- Target Recruit Count
- 8
- Registration Number
- NCT03649152
- Locations
- π¦πΊ
Westmead, Westmead, New South Wales, Australia
π¦πΊRenal Research, Gosford, New South Wales, Australia
π¦πΊBox Hill Hospital, Box Hill, Victoria, Australia
Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Dimerix Bioscience Pty Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT03627715
- Locations
- π¦πΊ
Melbourne Renal Research Group, Melbourne, Victoria, Australia
π¦πΊLiverpool Hospital, Liverpool, New South Wales, Australia
π¦πΊRoyal North Shore Hospital, St Leonards, New South Wales, Australia
Β© Copyright 2024. All Rights Reserved by MedPath